(1) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 375mg of nicotinic acid and having:

a nicotinic acid Cmax of about 3μg/ml;

a nicotinic acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nictoinic acid of about 6μghr/ml.

(2) An intermediate release nicotinic acid formulation of claim 1, wherein said nicotinic acid formulation is a tablet.

(3) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 375mg of nicotinic acid and having:

a nicotinuric acid Cmax of about 2μg/ml;

a nicotinuric acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nictoinuric acid of about 10μghr/ml.

(4) An intermediate release nicotinic acid formulation of claim 3, wherein said nicotinic acid formulation is a tablet.

(5) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 500mg of nicotinic acid and having:

a nicotinic acid Cmax in the range of from between about 1μg/ml and 10μg/ml;

a nicotinic acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nictoinic acid in the range of from between about 2μghr/ml and about 34μghr/ml.

(6) An intermediate release nicotinic acid formulation of claim 5, wherein the Cmax has a mean of about 4μg/ml and the AUC has a mean of about 9μghr/ml.

(7) An intermediate release nicotinic acid formulation of claim 5, wherein said nicotinic acid formulation is a tablet.

(8) An intermediate release nicotinic acid formulation of claim 6, wherein said nicotinic acid formulation is a tablet.

(9) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 500mg of nicotinic acid and having:

a nicotinuric acid Cmax in the range of from between about 2μg/ml and 3μg/ml;

a nicotinuric acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nicotinuric acid in the range of from between about 6μghr/ml and about 16μghr/ml.

(10) An intermediate release nicotinic acid formulation of claim 9, wherein the Cmax has a mean of about 2μg/ml and the AUC has a mean of about 9μghr/ml.

(11) An intermediate release nicotinic acid formulation of claim 9, wherein said nicotinic acid formulation is a tablet.

(12) An intermediate release nicotinic acid formulation of claim 10, wherein said nicotinic acid formulation is a tablet.

(13) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 750mg of nicotinic acid and having:

a nicotinic acid Cmax in the range of from between about 8μg/ml and 9μg/ml;

a nicotinic acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nictoinic acid in the range of from between about 21μghr/ml and about 22μghr/ml.

(14) An intermediate release nicotinic acid formulation of claim 13, wherein the Cmax has a mean of about 8μg/ml and the AUC has a mean of about 21μghr/ml.

(15) An intermediate release nicotinic acid formulation of claim 13, wherein said nicotinic acid formulation is a tablet.

(16) An intermediate release nicotinic acid formulation of claim 14, wherein said nicotinic acid formulation is a tablet.

(17) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 750mg of nicotinic acid and having:

a nicotinuric acid Cmax in the range of from between about 3μg/ml and 3.2μg/ml;

a nicotinuric acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nicotinuric acid in the range of from between about 11μghr/ml and about 13μghr/ml.

(18) An intermediate release nicotinic acid formulation of claim 17, wherein the Cmax has a mean of about 3μg/ml and the AUC has a mean of about 12μghr/ml.

(19) An intermediate release nicotinic acid formulation of claim 17, wherein said nicotinic acid formulation is a tablet.

(20) An intermediate release nicotinic acid formulation of claim 19, wherein said nicotinic acid formulation is a tablet.

(21) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 1000mg of nicotinic acid and having:

a nicotinic acid Cmax in the range of from between about 9μg/ml and 17μg/ml;

a nicotinic acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nictoinic acid in the range of from between about 24μghr/ml and about 43μghr/ml.

(22) An intermediate release nicotinic acid formulation of claim 21, wherein the Cmax has a mean of about 13μg/ml and the AUC has a mean of about 33μghr/ml.

(23) An intermediate release nicotinic acid formulation of claim 21, wherein said nicotinic acid formulation is a tablet.

(24) An intermediate release nicotinic acid formulation of claim 22, wherein said nicotinic acid formulation is a tablet.

(25) An intermediate release nicotinic acid formulation suitable for oral administration once-a-day for treating hyperlipidemia without causing drug-induced hepatotoxicity to a level which would require use of said intermediate release nicotinic acid formulation to be discontinued, said intermediate release nicotinic acid formulation containing at least about 1000mg of nicotinic acid and having:

a nicotinuric acid Cmax in the range of from between about 3μg/ml and 5μg/ml;

a nicotinuric acid Tmax in the range of between about 5.6 hours and about 6 hours; and

an AUC for nicotinuric acid in the range of from between about 12μghr/ml and about 19μghr/ml.

(26) An intermediate release nicotinic acid formulation of claim 25, wherein the Cmax has a mean of about 4μg/ml and the AUC has a mean of about 15μghr/ml.

(27) An intermediate release nicotinic acid formulation of claim 25, wherein said nicotinic acid formulation is a tablet.

(28) An intermediate release nicotinic acid formulation of claim 26, wherein said nicotinic acid formulation is a tablet.